CD84 as a therapeutic target for breaking immune tolerance in triple-negative breast cancer
Stav Rabani(Weizmann Institute of Science), Idit Shachar(Weizmann Institute of Science), Keren David(Weizmann Institute of Science), Shirly Becker-Herman(Weizmann Institute of Science), Bianca Pellegrino(Weizmann Institute of Science), Raju Pillai(City Of Hope National Medical Center), Emine Gulsen Gunes(City Of Hope National Medical Center), Aimin Li(City Of Hope National Medical Center), Bar Lampert(Weizmann Institute of Science), Steven T. Rosen(Unknown)
Cited by 12
Related Papers
Clinical End Points and Response Criteria in Mycosis Fungoides and Sézary Syndrome: A Consensus Statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer
|Journal of Clinical Oncology|2011|657
Enabling Technologies for Personalized and Precision Medicine
|Trends in biotechnology|2020|483
Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study
|The Lancet Oncology|2017|327
Cell-surface CD74 initiates a signaling cascade leading to cell proliferation and survival
|Blood|2006|312
Relapsed or Refractory Double-Expressor and Double-Hit Lymphomas Have Inferior Progression-Free Survival After Autologous Stem-Cell Transplantation
|Journal of Clinical Oncology|2016|187